Evidence map›Paper›PMID 30093861›Full record

ArticleFrontiers in pharmacology2018

Enhancement of Tumor Cell Death by Combining

Alberto Ramírez, Ana Conejo-García, Carmen Griñán-Lisón, Luisa C López-Cara, Gema Jiménez, Joaquín M Campos, Juan A Marchal, Houria Boulaiz

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Silver Nanoparticles fromNanomaterials (Basel, Switzerland) · 2021
    Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Alberto RamírezBiopathology and Medicine Regenerative Institute, University of Granada, Granada, Spain.
Ana Conejo-GarcíaDepartment of Pharmaceutical and Organic Chemistry, University of Granada, Granada, Spain.
Carmen Griñán-LisónBiopathology and Medicine Regenerative Institute, University of Granada, Granada, Spain.
Luisa C López-CaraDepartment of Pharmaceutical and Organic Chemistry, University of Granada, Granada, Spain.
Gema JiménezBiopathology and Medicine Regenerative Institute, University of Granada, Granada, Spain.
Joaquín M CamposDepartment of Pharmaceutical and Organic Chemistry, University of Granada, Granada, Spain.
Juan A MarchalBiopathology and Medicine Regenerative Institute, University of Granada, Granada, Spain.
Houria BoulaizBiopathology and Medicine Regenerative Institute, University of Granada, Granada, Spain.
Universidad de Granada · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

New treatment modalities are urgently needed to better manage advanced breast cancer. Combination therapies are usually more effective than monotherapy. In this context, the use of cyclic and acyclic

Indexed as

14-benzoxazepin-26-dichloropurinebreast cancercombined therapygef genegene therapy

Identifiers

PMID30093861
PMCPMC6070671
OpenAlexW2855082336

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.